Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NAD bounces Notox to FTC

This article was originally published in The Tan Sheet

Executive Summary

Claims for A.D. Pharma's alcohol-intoxication reducer have been referred to the Federal Trade Commission after the firm failed to make a "bona fide good faith attempt to bring its advertising into compliance with NAD's recommendations," the Council of Better Business Bureaus division says in an Aug. 19 release. Notox was the subject of a NAD inquiry in the spring (1"The Tan Sheet" May 3, 2004, In Brief). At issue were claims that clinical studies indicate the Panax ginseng/citrus reticulate supplement "combats the effects of alcohol intoxication." The watchdog group notes that the television commercial NAD objected to has been permanently discontinued...

You may also be interested in...

Notox gets buzzed by NAD

Statements that "clinical test results show that Notox...combats the effects of alcohol intoxication" should be modified, the National Advertising Division tells A.D. Pharma following a recent review. Implied and explicit claims on TV, radio, and print ads and testimonials for the Panax ginseng/citrus reticulate supplement, found during routine monitoring, are not supported by a trial in 10 male subjects, the watchdog group adds. NAD also was troubled by claims that could lead consumers to believe that "Notox allows product users to drink and drive." A.D. Pharma said it modified the television spot prior to NAD's inquiry, and plans on revising its website...

'Touchless Plants' To Virtually Trained Workforces - Indian Cos Share Digitalization Tips

Despite AI and digital analytics playing an increasing role in pharma, the industry lags others globally, a recent event heard. Meanwhile, top Indian players including Sun Pharma, Cipla and others shared what is driving their initiatives, ranging from a 'touchless factory' to virtual training and lessons learned along the way.

More IVD Mergers: Agilent Buys Resolution, Hologic Acquires Diagenode

Hologic made its third big acquisition of 2021 and Agilent agreed to pay up to $695m for Resolution Bioscience to extend its precision oncology capabilities.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts